---
schema_version: "secwatch.filing_event.v1"
accession: "0001145197-23-000037"
form_type: "8-K"
ticker: "PODD"
cik: "0001145197"
company_name: "INSULET CORP"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:59:01.554315+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insulet Q1 revenue $358.1M (+21% YoY); U.S. Omnipod revenue up 49%

## Summary
- Net income $23.8M ($0.34 diluted EPS) vs $27.8M ($0.40) prior year.
- Total Omnipod revenue $357.6M (+32.7% YoY); U.S. segment $259.0M (+48.8%).
- Adjusted EBITDA $48.8M (13.6% of revenue) vs $63.0M (21.3%) prior year.
- FDA cleared Omnipod GO basal-only pod; Omnipod 5 UK launch on track mid-year.
- Gross margin 67.2% down 380 bps; adjusted gross margin 64.9% excluding MDC charges.

## SEC filing metadata
- accession: 0001145197-23-000037
- form_type: 8-K
- ticker: PODD
- cik: 0001145197
- company_name: INSULET CORP
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000037/0001145197-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000037/podd-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001145197-23-000037
- JSON: https://secwatch.observer/filing/0001145197-23-000037.json
- Plain text: https://secwatch.observer/filing/0001145197-23-000037.txt

## Key facts
- Earnings Releases
  INSULET CORP reported first quarter ended March 31, 2023 results: revenue $358.1 million, net income $23.8 million, EPS $0.34 per diluted share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $358.1 million
  - Net income: $23.8 million
  - EPS: $0.34 per diluted share
  - Result: reported results
  source text: First Quarter Financial Highlights: • First quarter 2023 revenue of $358.1 million, up 21.2%, or 23.3% in constant currency 1 , compared to $295.4 million in the prior year ◦ Total Omnipod revenue of $357.6 million, an increase of 32.7%, or 34.9% in constant currency ◦ U.S. Omnipod revenue of $259.0 million, an increase of 48.8% ◦ International Omnipod revenue of $98.6 million, an increase of 3.4%, or an increase of 9.6% in constant currency ◦ Drug Delivery revenue of $0.5 million, a decrease of 98.1% • Gross margin of 67.2%, down 380 basis points. Adjusted gross margin 1 of 64.9% excludes income of $8.0 million associated with the voluntary medical device correction (MDC) notices issued in 2022 • Operating income of $27.7 million, or 7.7% of revenue, compared to $37.9 million, or 12.8% of revenue, in the prior year. Adjusted operating income 1 of $19.7 million, or 5.5%, excludes income of $8.0 million noted above • Net income of $23.8 million, or $0.34 per diluted share, compared to $
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000037/0001145197-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.